keyword
MENU ▼
Read by QxMD icon Read
search

B cell depletion ME CFS

keyword
https://www.readbyqxmd.com/read/27536947/serum-baff-and-april-levels-t-lymphocyte-subsets-and-immunoglobulins-after-b-cell-depletion-using-the-monoclonal-anti-cd20-antibody-rituximab-in-myalgic-encephalopathy-chronic-fatigue-syndrome
#1
Sigrid Lunde, Einar K Kristoffersen, Dipak Sapkota, Kristin Risa, Olav Dahl, Ove Bruland, Olav Mella, Øystein Fluge
Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We have previously suggested clinical benefit from B-cell depletion using the monoclonal anti-CD20 antibody rituximab in a randomized and placebo-controlled study. Prolonged responses were then demonstrated in an open-label phase-II study with maintenance rituximab treatment. Using blood samples from patients in the previous two clinical trials, we investigated quantitative changes in T-lymphocyte subsets, in immunoglobulins, and in serum levels of two B-cell regulating cytokines during follow-up...
2016: PloS One
https://www.readbyqxmd.com/read/27275835/a-role-for-the-intestinal-microbiota-and-virome-in-myalgic-encephalomyelitis-chronic-fatigue-syndrome-me-cfs
#2
REVIEW
Navena Navaneetharaja, Verity Griffiths, Tom Wileman, Simon R Carding
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous disorder of significant societal impact that is proposed to involve both host and environmentally derived aetiologies that may be autoimmune in nature. Immune-related symptoms of at least moderate severity persisting for prolonged periods of time are common in ME/CFS patients and B cell depletion therapy is of significant therapeutic benefit. The origin of these symptoms and whether it is infectious or inflammatory in nature is not clear, with seeking evidence of acute or chronic virus infections contributing to the induction of autoimmune processes in ME/CFS being an area of recent interest...
2016: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/26646713/extended-b-cell-phenotype-in-patients-with-myalgic-encephalomyelitis-chronic-fatigue-syndrome-a-cross-sectional-study
#3
F Mensah, A Bansal, S Berkovitz, A Sharma, V Reddy, M J Leandro, G Cambridge
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a heterogeneous condition of unknown aetiology characterized by multiple symptoms including fatigue, post-exertional malaise and cognitive impairment, lasting for at least 6 months. Recently, two clinical trials of B cell depletion therapy with rituximab (anti-CD20) reported convincing improvement in symptoms. A possible but undefined role for B cells has therefore been proposed. Studies of the relative percentages of B cell subsets in patients with ME/CFS have not revealed any reproducible differences from healthy controls (HC)...
May 2016: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/26132314/b-lymphocyte-depletion-in-myalgic-encephalopathy-chronic-fatigue-syndrome-an-open-label-phase-ii-study-with-rituximab-maintenance-treatment
#4
Øystein Fluge, Kristin Risa, Sigrid Lunde, Kine Alme, Ingrid Gurvin Rekeland, Dipak Sapkota, Einar Kleboe Kristoffersen, Kari Sørland, Ove Bruland, Olav Dahl, Olav Mella
BACKGROUND: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We previously reported a pilot case series followed by a small, randomized, placebo-controlled phase II study, suggesting that B-cell depletion using the monoclonal anti-CD20 antibody rituximab can yield clinical benefit in ME/CFS. METHODS: In this single-center, open-label, one-armed phase II study (NCT01156909), 29 patients were included for treatment with rituximab (500 mg/m2) two infusions two weeks apart, followed by maintenance rituximab infusions after 3, 6, 10 and 15 months, and with follow-up for 36 months...
2015: PloS One
https://www.readbyqxmd.com/read/24068616/the-emerging-role-of-autoimmunity-in-myalgic-encephalomyelitis-chronic-fatigue-syndrome-me-cfs
#5
REVIEW
Gerwyn Morris, Michael Berk, Piotr Galecki, Michael Maes
The World Health Organization classifies myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs) as a nervous system disease. Together with other diseases under the G93 heading, ME/cfs shares a triad of abnormalities involving elevated oxidative and nitrosative stress (O&NS), activation of immuno-inflammatory pathways, and mitochondrial dysfunctions with depleted levels of adenosine triphosphate (ATP) synthesis. There is also abundant evidence that many patients with ME/cfs (up to around 60 %) may suffer from autoimmune responses...
April 2014: Molecular Neurobiology
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"